Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.

Journal of clinical microbiology - 1 Nov 2018

Oštrbenk Anja, Xu Lan, Arbyn Marc, Poljak Mario

Abstract excerpt

In 2012, VALidation of human papillomavirus (HPV) GENotyping Tests (VALGENT) was initiated to provide a formalized and uniform study framework for comparison and validation of HPV assays with genotyping capability. In VALGENT-3, the clinical and analytical performance of Anyplex II HPV HR detection (Anyplex) was compared to that of the Hybrid Capture 2 HPV DNA test (hc2) and the cobas 4800 HPV test (cobas). The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cervix Uteri
Share to Early Detection of Cancer
Share to Genotyping Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Papillomaviridae

Share to Papillomavirus Infections

Share to Sensitivity and Specificity

Share to Slovenia

Share to Uterine Cervical Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 30209184
DOI: 10.1128/JCM.01176-18
PMCID: PMC6204677

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.PMID 30209184Read ↗

Allplex HPV HR Detection assay fulfils all clinical performance and reproducibility validation requirements for primary cervical cancer screening.Semantic proximity Read ↗

Clinical Evaluation of INNO-LiPA HPV Genotyping EXTRA II Assay Using the VALGENT FrameworkSemantic proximity Read ↗

Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.Semantic proximity Read ↗

Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework.Semantic proximity Read ↗

Anyplex II HPV28 detection and Anyplex II HPV HR detection assays are highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities.Semantic proximity Read ↗

Comparison of the performance of Anyplex II HPV HR, the Cobas 4800 human papillomavirus test and Hybrid Capture 2.Semantic proximity Read ↗

Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework.Semantic proximity Read ↗

Clinical and Analytical Evaluation of the Alinity m HR HPV Assay within the VALGENT-3 Framework.Semantic proximity Read ↗

Accuracy of Allplex HPV HR Detection Full Genotyping Assay on Cervical Samples Compared to Vaginal Self-Samples.Semantic proximity Read ↗

Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.Semantic proximity Read ↗

Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.Semantic proximity Read ↗

Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT frameworkSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.